½ÃÀ庸°í¼­
»óǰÄÚµå
1594544

ÇÙ»ê °Ë»ç ½ÃÀå : ÀûÀÀÁõº°, Á¦Ç°º°, ¹æ¹ýº°, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Nucleic Acid Testing Market by Indication (Cancer, Forensic Testing, Genetic & Mitochondrial Disorders), Product (Consumables, Nucleic Acid Test Kits), Technique, End User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 185 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÇÙ»ê °Ë»ç ½ÃÀåÀº 2023³â 34¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ°í 2024³â¿¡´Â 37¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CAGR 10.30%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 68¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÇÙ»ê °Ë»ç(NAT)´Â DNA¿Í RNA¿Í °°Àº À¯Àü ¹°ÁúÀ» °ËÃâ ¹× ÁõÆøÇÏ¿© º´¿øÃ¼ ¹× ÀÌ»óÀ» ½Äº°ÇÏ´Â ±â´ÉÀ» °¡Áø ºÐÀÚÁø´Ü ½ÃÀåÀÇ Áß¿äÇÑ ºÎ¹®ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Çʿ伺Àº ƯÈ÷ COVID-19 ÆÒµ¥¹Í°ú °¨¿°ÁõÀÇ Áõ°¡¿Í °°Àº ±Û·Î¹ú º¸°Ç ¹®Á¦¿¡ ºñÃß¾î º¼ ¶§, Á¤È®ÇÑ Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. NATÀÇ ÀÀ¿ë ºÐ¾ß´Â Ç÷¾× °Ë»ç, °¨¿° Áø´Ü, Á¾¾çÇÐ µî ´Ù¾çÇÑ ºÐ¾ß¿¡ °ÉÃÄ ÀÇ·á ȯ°æ, ¿¬±¸ ±â°ü ¹× »ý¸í°øÇÐ ±â¾÷¿¡ ¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ÁõÆø¹ýÀÇ ±â¼ú ¹ßÀü, ÀÇ·áºñ ÁöÃâ Áõ°¡, Áúº´ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯ÀüÀÚ ¹× À¯Àüü µ¥ÀÌÅÍ¿¡ ±â¹ÝÇÑ ¸ÂÃãÇü ÀÇ·á·Î ÀÎÇØ Á¤¹Ð Ä¡·áÀÇ ±âȸ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº °Ë»ç ºñ¿ë, ±ÔÁ¦ À庮, Àü¹® °Ë»ç ÀÎÇÁ¶óÀÇ Çʿ伺 µî ¿©·¯ °¡Áö ¹®Á¦Á¡ÀÌ Á¸ÀçÇϸç, ƯÈ÷ Àú°³¹ß Áö¿ª¿¡¼­ÀÇ º¸±ÞÀ» ÀúÇØÇÒ ¼ö ÀÖ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí, ÇöÀå °Ë»çÀÇ Çõ½Å°ú ´ú ħ½ÀÀûÀÎ ½Ã·á äÃë ¹æ¹ýÀÇ °³¹ßÀº »ç¿ëÀÚ Ä£È­ÀûÀÌ°í ½Å¼ÓÇÑ °Ë»ç ¼Ö·ç¼ÇÀ» ÃËÁøÇÒ ¼ö ÀÖ´Â Èï¹Ì·Î¿î ±âȸ¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, AI ¹× ¸Ó½Å·¯´×°ú NATÀÇ ÅëÇÕÀº µ¥ÀÌÅÍ ÇØ¼®¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ Áø´Ü Á¤È®µµ¿Í 󸮷®À» Çâ»ó½Ãų ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. Áø´Ü Á¤È®µµ¿Í 󸮷®À» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ºñÁî´Ï½º ¼ºÀåÀ» À§ÇØ ±â¾÷µéÀº ¿¬±¸ °³¹ßÀÇ ±âȸ°¡ ¹«¸£ÀÍÀº ºÐ¾ßÀÎ º¹ÀâÇÑ ½ÇÇè½Ç ȯ°æ¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ÁÙ¿©ÁÖ´Â ÈÞ´ë°¡ °¡´ÉÇÏ°í ºñ¿ë È¿À²ÀûÀΠŰƮ °³¹ß¿¡ ÁýÁßÇØ¾ß ÇÕ´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿Í Çù·ÂÇÏ¿© ƯÁ¤ ¿ä±¸ »çÇ×À» ÀÌÇØÇÏ°í ½ÅÈï ½ÃÀå ÁøÃâÀ» À§ÇÑ ÆÄÆ®³Ê½ÊÀ» ±¸ÃàÇÏ¸é °æÀï·ÂÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀÌ Á¡Â÷ ºÐ»êÇü °Ë»ç ȯ°æÀ¸·Î À̵¿ÇÔ¿¡ µû¶ó, È®Àå °¡´ÉÇϰí Ç¥ÁØÈ­µÈ ¼Ö·ç¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ´É·ÂÀÌ ¸Å¿ì Áß¿äÇØÁú °ÍÀÔ´Ï´Ù. ÇÑ¹ß ¾Õ¼­ ³ª°¡±â À§Çؼ­´Â ±ÔÁ¦ ȯ°æ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ´ëÀÀ°ú ÁøÈ­ÇÏ´Â ±â¼ú ȯ°æ¿¡ ´ëÇÑ ¹ÎøÇÑ ÀûÀÀÀÌ ÇÊ¿äÇϸç, ƯÈ÷ ¸ð¹ÙÀÏ Çコ ¾ÖÇø®ÄÉÀ̼ÇÀÇ »õ·Î¿î °¡´É¼º¿¡ ÁÖ¸ñÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ[2023] 34¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2024] 37¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2030] 68¾ï 3,000¸¸ ´Þ·¯
CAGR(%) 10.30%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ÇÙ»ê °Ë»ç ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÇÙ»ê °Ë»ç ½ÃÀåÀº ¼ö¿ä¿Í °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ÃËÁø¿äÀÎ
    • ¾Ï ¹× ±âŸ °¨¿°¼º Áúȯ ȯÀÚ Áõ°¡
    • Àΰ£ À¯ÀüÀÚ °Ë»çÀÇ »ó¿ëÈ­ Áõ°¡
    • ´ëÀ¯Çິ ´ëÀÀ ¹× ±ÙÀý¿¡ ´ëÇÑ ¼ö¿ä ±ÞÁõ
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • ¸·´ëÇÑ ¿¬±¸ °³¹ß ºñ¿ë
  • ½ÃÀå ±âȸ
    • °Ë»ç ´É·Â È®´ë¸¦ À§ÇÑ ¸Å·ÂÀûÀÎ ÀÚ±Ý Á¶´ÞÀÇ Àå°ú Á¤ºÎ Áö¿ø
    • Á¤ºÎÀÇ ½ÂÀÎ ¹× »óȯ Áõ°¡
  • ½ÃÀå °úÁ¦
    • º¹ÀâÇÑ Àåºñ¿Í ±â¼ú

Porter's Five Forces : ÇÙ»ê °Ë»ç ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï »óȲÀ» ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» º¸¿ÏÇϸç ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇÔÀ¸·Î½á º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÇÙ»ê °Ë»ç ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÇÙ»ê °Ë»ç ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ÇÙ»ê °Ë»ç ½ÃÀå¿¡¼­ÀÇ °æÀï »óȲ ÆÄ¾Ç

ÇÙ»ê °Ë»ç ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ÇÙ»ê °Ë»ç ½ÃÀå¿¡¼­ÀÇ °ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÇÙ»ê °Ë»ç ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î º¥´õ¸¦ Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÇÙ»ê °Ë»ç ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ ÇÙ»ê °Ë»ç ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æ ã±â

ÇÙ»ê °Ë»ç ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ ±â¾÷Àº °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï »óȲÀ» öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº ¾îµðÀΰ¡?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õÀÇ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÇÙ»ê °Ë»ç ½ÃÀå : ÀûÀÀÁõº°

  • ¾Ï
  • ¹ýÀÇÇÐ °Ë»ç
  • À¯Àü¼º Áúȯ ¹× ¹ÌÅäÄܵ帮¾Æ Áúȯ
  • °¨¿°Áõ

Á¦7Àå ÇÙ»ê °Ë»ç ½ÃÀå : Á¦Ç°º°

  • ¼Ò¸ðǰ
  • ÇÙ»ê °Ë»ç ŰƮ

Á¦8Àå ÇÙ»ê °Ë»ç ½ÃÀå : ±â¼úº°

  • ÇÁ·Îºê ÁõÆø ½Ã½ºÅÛ
  • ½ÅÈ£ ÁõÆø
  • Ÿ°Ù ÁõÆø ½Ã½ºÅÛ

Á¦9Àå ÇÙ»ê °Ë»ç ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • º´¸®ÇÐ ¿¬±¸½Ç
  • Á¶»ç±â°ü

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ÇÙ»ê °Ë»ç ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇÙ»ê °Ë»ç ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÇÙ»ê °Ë»ç ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦13Àå °æÀï »óȲ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • 23andMe, Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ARUP Laboratories
  • Asuragen Inc.
  • Beckman Coulter, Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomerieux SA
  • Cepheid
  • F. Hoffmann-La Roche Ltd.
  • Gen-Probe, Inc.
  • Illumina, Inc.
  • Novartis AG
  • Thermo Fisher Scientific Inc.
ksm 24.11.28

The Nucleic Acid Testing Market was valued at USD 3.43 billion in 2023, expected to reach USD 3.79 billion in 2024, and is projected to grow at a CAGR of 10.30%, to USD 6.83 billion by 2030.

Nucleic Acid Testing (NAT) represents a significant segment within the molecular diagnostics market, equipped to detect and amplify genetic material like DNA and RNA to identify pathogens or anomalies. Its necessity stems from the growing demand for accurate diagnostic tools, especially in light of global health challenges such as the COVID-19 pandemic and rising incidences of infectious diseases. NAT's applications span across diverse segments including blood screening, infectious disease diagnosis, and oncology, serving healthcare settings, research institutions, and biotechnology firms. Key growth factors include technological advancements in amplification methods, increased healthcare expenditures, and heightened awareness of early disease detection. Moreover, personalization in medicine, driven by genetic and genomic data, opens opportunities in precision therapies. However, the market faces challenges such as high test costs, regulatory hurdles, and the requirement for specialized laboratory infrastructure, which could hamper widespread adoption, especially in underdeveloped regions. Nevertheless, exciting opportunities lie in point-of-care testing innovations and the development of less invasive sample collection methods, fostering user-friendly and rapid testing solutions. The integration of AI and machine learning with NAT could also revolutionize data interpretation, enhancing diagnostic accuracy and throughput. For business growth, companies should focus on developing portable, cost-effective nucleic acid testing kits that reduce dependency on complex lab settings, an area ripe for research and development. Collaborations with healthcare providers to understand specific needs and partnerships for expanding into emerging markets can provide a competitive edge. As the market gradually transitions towards decentralized testing environments, the ability to offer scalable and standardized solutions will be crucial. To stay ahead, continuous focus on regulatory compliance and agile adaptation to evolving technological landscapes will be necessary, especially concerning emerging potential for mobile health applications.

KEY MARKET STATISTICS
Base Year [2023] USD 3.43 billion
Estimated Year [2024] USD 3.79 billion
Forecast Year [2030] USD 6.83 billion
CAGR (%) 10.30%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nucleic Acid Testing Market

The Nucleic Acid Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising cases of cancer and other infectious diseases
    • Increased commercialization of human genetic tests
    • Exponential need in pandemic control and eradication
  • Market Restraints
    • Huge expenditure on R&D
  • Market Opportunities
    • Attractive funding space and government support to expand testing capabilities
    • Increasing government approvals and reimbursements available
  • Market Challenges
    • Complex instrumentation and technology

Porter's Five Forces: A Strategic Tool for Navigating the Nucleic Acid Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nucleic Acid Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nucleic Acid Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nucleic Acid Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nucleic Acid Testing Market

A detailed market share analysis in the Nucleic Acid Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nucleic Acid Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nucleic Acid Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Nucleic Acid Testing Market

A strategic analysis of the Nucleic Acid Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Nucleic Acid Testing Market, highlighting leading vendors and their innovative profiles. These include 23andMe, Inc., Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, Asuragen Inc., Beckman Coulter, Inc., Becton Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerieux SA, Cepheid, F. Hoffmann-La Roche Ltd., Gen-Probe, Inc., Illumina, Inc., Novartis AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Nucleic Acid Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Cancer, Forensic Testing, Genetic & Mitochondrial Disorders, and Infectious Disease.
  • Based on Product, market is studied across Consumables and Nucleic Acid Test Kits.
  • Based on Technique, market is studied across Probe Amplification Systems, Signal Amplification, and Target Amplification Systems.
  • Based on End User, market is studied across Hospitals, Pathology Laboratories, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising cases of cancer and other infectious diseases
      • 5.1.1.2. Increased commercialization of human genetic tests
      • 5.1.1.3. Exponential need in pandemic control and eradication
    • 5.1.2. Restraints
      • 5.1.2.1. Huge expenditure on R&D
    • 5.1.3. Opportunities
      • 5.1.3.1. Attractive funding space and government support to expand testing capabilities
      • 5.1.3.2. Increasing government approvals and reimbursements available
    • 5.1.4. Challenges
      • 5.1.4.1. Complex instrumentation and technology
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Nucleic Acid Testing Market, by Indication

  • 6.1. Introduction
  • 6.2. Cancer
  • 6.3. Forensic Testing
  • 6.4. Genetic & Mitochondrial Disorders
  • 6.5. Infectious Disease

7. Nucleic Acid Testing Market, by Product

  • 7.1. Introduction
  • 7.2. Consumables
  • 7.3. Nucleic Acid Test Kits

8. Nucleic Acid Testing Market, by Technique

  • 8.1. Introduction
  • 8.2. Probe Amplification Systems
  • 8.3. Signal Amplification
  • 8.4. Target Amplification Systems

9. Nucleic Acid Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Pathology Laboratories
  • 9.4. Research Institutes

10. Americas Nucleic Acid Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Nucleic Acid Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Nucleic Acid Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 23andMe, Inc.
  • 2. Abbott Laboratories
  • 3. Agilent Technologies, Inc.
  • 4. ARUP Laboratories
  • 5. Asuragen Inc.
  • 6. Beckman Coulter, Inc.
  • 7. Becton Dickinson and Company
  • 8. Bio-Rad Laboratories, Inc.
  • 9. Biomerieux SA
  • 10. Cepheid
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Gen-Probe, Inc.
  • 13. Illumina, Inc.
  • 14. Novartis AG
  • 15. Thermo Fisher Scientific Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦